药捷安康-B(02617)拟实行H股全流通

Core Viewpoint - The company plans to convert 44.9711 million domestic shares held by 10 shareholders into H-shares, representing approximately 11.33% of the total issued shares as of the announcement date [1] Group 1 - The board of directors has approved the application to submit to the China Securities Regulatory Commission [1] - The conversion of domestic shares into H-shares is contingent upon obtaining all necessary approvals, including from the China Securities Regulatory Commission and the Stock Exchange [1] - The converted H-shares will be eligible for listing and trading on the main board of the Stock Exchange [1]